The questions submitted by the advocates follow:
Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.
Advocates Request Answers To These Questions in Writing
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.
As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment.
Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.
The Cancer Letter has published a number of excellent pieces lately on the importance of supporting and encouraging trainees and junior investigators during these uncertain times.
Ousted from her position as director of the Centers for Disease Control and Prevention less than a month after her confirmation, Susan Monarez has now had the chance to tell her side of the story before Congress.
